Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Infectious Disease Diagnostics Market – Insights
Infectious diseases are caused by pathogens such as bacteria, viruses, fungi or parasites. Infectious diseases spread from person to person either through direct contact or indirectly through insect bites or other vectors like food, soil, water, and air. Diagnosis is the identification of disease causing agents by studying the symptoms exhibited by the afflicted individual. It plays a vital role in making decisions regarding accurate treatment of infectious and other diseases.
The global infectious disease diagnostics market is estimated to account for US$ 1,131.4 Mn in terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of 2027.
Global Infectious Disease Diagnostics Market: Drivers
Increasing prevalence of infectious diseases is expected to propel growth of the global infectious disease diagnostics market over the forecast period. For instance, as of February 23, 2020, there were 76,936 reported cases of in mainland China and 1,875 cases of coronavirus disease 2019 in locations outside mainland China and the number of associated deaths was 2,462.
Moreover, funding related to infectious disease diagnostics is also expected to aid in growth of the market. For instance, in January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases.
Asia Pacific region held dominant position in the global infectious disease diagnostics market in 2018, accounting for 27.0% share in terms of value, followed by Africa.
Global Infectious Disease Diagnostics Market: Restraints
High price of molecular-based test kits is expected to hinder growth of the market. Molecular-based test kits play a major part in the diagnosis of infectious diseases. However, the high price of molecular test kits is leading to their low adoption, especially in emerging countries.
Lack of reimbursement for certain infectious diseases is also expected to limit growth of the market. For instance, in July 2018, the Centers for Medicare & Medicaid Services significantly reduced reimbursement for evaluation and management of complex cases such as those suffering from infectious diseases.
Global Infectious Disease Diagnostics Market: Opportunities
Introduction of cost-effective and reliable test kits is expected to offer lucrative growth opportunities for players in the market. Currently, very few effective diagnostic test kits are available for infectious diseases. Unavailability of effective diagnostic tools and high price of existing test kits has triggered the need for cost-effective test kits with high specificity and sensitivity.
Moreover, R&D in diagnostic kits is also expected to aid in growth of the market. For instance, in September 2019, researchers from University of Helsinki, Finland, reported that the antibody response against Puumala orthohantavirus can be measured at a high sensitivity and specificity with the unorthodox point-of-care assay LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection, using urine as sample matrix.
Diagnostic centers segment in the global infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018 and is expected to reach US$ 958.7 Mn by 2027 at a CAGR of 8.5% during the forecast period.
Market Trends/Key Takeaways
The emphasis on development of point-of-care tests for diagnosis of various infectious diseases is high. Point-of-care tests provide faster results without the sample being sent to diagnostic laboratories for testing. This factor is expected to result in higher demand for point-of-care tests. Companies such as Alere and Cepheid are focusing on developing analytical systems, which provide near patient molecular assay results.
Currently available diagnostic tests are slow and have low specificity and sensitivity. Hence, the market is witnessing a shift from combined tests to rapid diagnostic tests for whole microbial genome sequencing.
Global Infectious Disease Diagnostics Market: Competitive Landscape
Major players operating in the global infectious disease diagnostics market include, Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
Global Infectious Disease Diagnostics Market: Key Developments
Major players in the market are focused on launching new services to enhance their market share. For instance, in March 2020, Quest Diagnostics announced to launch a coronavirus (COVID-19) test service that aids the presumptive detection of nucleic acid in respiratory specimens of patients meeting the Centers for Disease Control and Prevention’s clinical criteria for COVID-19 testing.
Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2020, Thermo Fisher Scientific Inc. announced to acquire QIAGEN N.V., a provider of molecular diagnostics and sample preparation technologies.